(0.27%) 5 113.62 points
(0.29%) 38 349 points
(0.30%) 15 976 points
(-0.93%) $83.07
(5.67%) $2.03
(0.37%) $2 355.80
(0.44%) $27.66
(3.99%) $958.85
(-0.21%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.59%
@ $1.435
発行日: 15 2月 2024 @ 05:31
リターン: 7.32%
前回のシグナル: 2月 14 - 23:52
前回のシグナル:
リターン: -3.68 %
Live Chart Being Loaded With Signals
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...
Stats | |
---|---|
本日の出来高 | 0.00 |
平均出来高 | 969 866 |
時価総額 | 128.53M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $-0.300 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.890 |
ATR14 | $0.00400 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Tcg Opportunity Iii Gp, Llc | Buy | 1 000 | Common Stock |
2024-04-05 | Tcg Opportunity Iii Gp, Llc | Sell | 44 000 | Common Stock |
2024-04-05 | Column Group Gp, Lp | Buy | 1 000 | Common Stock |
2024-04-05 | Column Group Gp, Lp | Sell | 44 000 | Common Stock |
2024-04-05 | Column Group L P | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
-56.35 |
Last 100 transactions |
Buy: 3 241 050 | Sell: 9 885 031 |
ボリューム 相関
NGM Biopharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
NGM Biopharmaceuticals 相関 - 通貨/商品
NGM Biopharmaceuticals 財務諸表
Annual | 2023 |
収益: | $4.42M |
総利益: | $2.20M (49.72 %) |
EPS: | $-1.730 |
FY | 2023 |
収益: | $4.42M |
総利益: | $2.20M (49.72 %) |
EPS: | $-1.730 |
FY | 2022 |
収益: | $55.33M |
総利益: | $49.35M (89.19 %) |
EPS: | $-1.990 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.555 |
Financial Reports:
No articles found.
NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。